IMMUNDIAGNOSTIK AG

Their core work

IMMUNDIAGNOSTIK AG is a German SME that develops and manufactures immunological test systems and in vitro diagnostic (IVD) assays for clinical and laboratory use. Their core business is translating biomarker science into practical diagnostic products — kits and assays that detect specific biological signals in patient samples. Their H2020 work reveals two complementary directions: commercializing point-of-care (POC) diagnostic formats through an SME Instrument feasibility study, and engaging in basic-to-applied research on muscle physiology through an MSCA mobility consortium. They sit at the interface between laboratory research and clinical diagnostics product development.

What they specialise in

How they've shifted over time

With only two projects spanning 2015–2016 and no keyword metadata available, a detailed evolution analysis is not possible. What can be observed is a shift from a commercially-driven clinical validation project (QuantOnCal, SME Instrument) toward participation in a longer, academically-oriented research collaboration (Muscle Stress Relief, MSCA-RISE). This may reflect a deliberate strategy to build scientific credibility and extend their biomarker portfolio beyond their existing assay catalogue. No post-2016 H2020 data is available to confirm whether either direction became dominant.

The combination of a commercialization-focused SME Instrument project and an MSCA-RISE research mobility program suggests they were positioning themselves as both a diagnostic product developer and a research-capable partner — though the limited data window makes any strong directional claim speculative.

How they like to work

IMMUNDIAGNOSTIK AG has taken both coordinator and participant roles across their two H2020 projects, indicating flexibility in how they engage with consortia. Despite only two projects, they connected with 20 unique partners across 8 countries, which is unusually broad for an SME of this size and suggests they join medium-to-large international consortia rather than small bilateral arrangements. As an SME, they likely contribute as a diagnostic industry partner bringing product development and commercial validation expertise to otherwise research-heavy consortia.

IMMUNDIAGNOSTIK AG has reached 20 unique consortium partners across 8 countries from just two projects — a high connectivity ratio for an SME at this funding level. Their network spans European research institutions and likely includes academic medical centers and clinical partners given their diagnostics focus.

What sets them apart

IMMUNDIAGNOSTIK AG is a rare example of a small German diagnostics manufacturer that has engaged in EU research both as a commercial innovator (SME Instrument) and as a scientific collaborator (MSCA-RISE). Most IVD SMEs at this scale either pursue commercialization grants or basic research partnerships — not both simultaneously. For consortium builders, they offer a credible bridge between laboratory biomarker research and the clinical product development pipeline, which is a bottleneck in many health research projects.

Highlights from their portfolio

• QuantOnCal
  Their only funded H2020 project and their sole coordinator role — an SME Instrument Phase 1 feasibility study, which is competitive and validates their commercial diagnostic innovation capability.
• Muscle stress relief
  A four-year MSCA-RISE program (2016–2020) linking basic muscle physiology research to applied outcomes, showing their willingness to engage in long-horizon academic consortia beyond their commercial core.